BACKGROUND AND PURPOSE: Most patients with cerebral sinus thrombosis (CST) recover after treatment with heparin, but a subgroup has a poor prognosis. Those patients may benefit from endovascular thrombolysis. METHODS: Prospective case series. Patients with sinus thrombosis were selected for thrombolysis if they had an altered mental status, coma, straight sinus thrombosis, or large space-occupying lesions. Urokinase was infused into the sinuses (bolus 120 to 600 x 10(3) U; then 100 x 10(3) U/h) via a jugular catheter, in 15 cases combined with mechanical thrombus disruption or removal. RESULTS: We treated 20 patients (16 women), mean age 32 years. Twelve patients were comatose and 14 had hemorrhagic infarcts before thrombolysis. Twelve patients recovered (Rankin score 0 to 2), 2 survived with handicaps, and 6 died. Factors associated with a fatal outcome were leukemia (3/6 versus 0/14, P=0.02) and large hemorrhagic infarcts (4/6 versus 2/14, P=0.04). Seizures were less frequent in the fatal cases (P=0.05). Patients who died had a larger mean lesion surface than survivors (30.5 versus 13.6 cm(2); P=0.03), larger midline shift (5.2 versus 1.7 mm; P=0.02), and a more rapid course (2.7 versus 8.2 days; P=0.01). Five patients who died had large hemispheric infarcts and edema before thrombolysis, causing herniation. Five patients had increased cerebral hemorrhage (3 minor, 2 major) after thrombolysis. CONCLUSIONS: Thrombolysis can be effective for severe sinus thrombosis, but patients may deteriorate because of increased cerebral hemorrhage. Patients with large infarcts and impending herniation did not benefit.
BACKGROUND AND PURPOSE: Most patients with cerebral sinus thrombosis (CST) recover after treatment with heparin, but a subgroup has a poor prognosis. Those patients may benefit from endovascular thrombolysis. METHODS: Prospective case series. Patients with sinus thrombosis were selected for thrombolysis if they had an altered mental status, coma, straight sinus thrombosis, or large space-occupying lesions. Urokinase was infused into the sinuses (bolus 120 to 600 x 10(3) U; then 100 x 10(3) U/h) via a jugular catheter, in 15 cases combined with mechanical thrombus disruption or removal. RESULTS: We treated 20 patients (16 women), mean age 32 years. Twelve patients were comatose and 14 had hemorrhagic infarcts before thrombolysis. Twelve patients recovered (Rankin score 0 to 2), 2 survived with handicaps, and 6 died. Factors associated with a fatal outcome were leukemia (3/6 versus 0/14, P=0.02) and large hemorrhagic infarcts (4/6 versus 2/14, P=0.04). Seizures were less frequent in the fatal cases (P=0.05). Patients who died had a larger mean lesion surface than survivors (30.5 versus 13.6 cm(2); P=0.03), larger midline shift (5.2 versus 1.7 mm; P=0.02), and a more rapid course (2.7 versus 8.2 days; P=0.01). Five patients who died had large hemispheric infarcts and edema before thrombolysis, causing herniation. Five patients had increased cerebral hemorrhage (3 minor, 2 major) after thrombolysis. CONCLUSIONS: Thrombolysis can be effective for severe sinus thrombosis, but patients may deteriorate because of increased cerebral hemorrhage. Patients with large infarcts and impending herniation did not benefit.
Authors: Leonard Ll Yeo; Priscillia Ps Lye; Kong Wan Yee; Yang Cunli; Tu Tian Ming; Andrew Fw Ho; Vijay K Sharma; Bernard Pl Chan; Benjamin Yq Tan; Anil Gopinathan Journal: Clin Neuroradiol Date: 2020-06-11 Impact factor: 3.649
Authors: Sudeepta Dandapat; Edgar A Samaniego; Viktor Szeder; Fazeel M Siddiqui; Gary R Duckwiler; Ume Kiddy; Waldo R Guerrero; Binbin Zheng; David Hasan; Colin Derdeyn; Santiago Ortega-Gutierrez Journal: Interv Neuroradiol Date: 2019-07-31 Impact factor: 1.610
Authors: R Mohammadian; B Sohrabi; R Mansourizadeh; F Mohammadian; A Nazempour; M Farhoudi; A Pashapour; A A Taher Aghdam; A Hashemzadeh; M Pourkakrodi Journal: Interv Neuroradiol Date: 2012-03-16 Impact factor: 1.610
Authors: Merel Jj Verhagen; Adriaan Cgm van Es; Geert J Lycklama À Nijeholt; Korné Jellema; Jonathan Coutinho; Ido R van den Wijngaard Journal: Interv Neuroradiol Date: 2017-05-17 Impact factor: 1.610